Impact of Insulin-Derived Amyloidosis on Glycemic Control and Insulin Dosing
Clin Diabetes
.
2022 Summer;40(3):380-384.
doi: 10.2337/cd21-0118.
Authors
Aaron Estep
1
,
Jarrod Uhrig
2
,
Curtis Bower
3
,
Robert Jarrett
4
5
Affiliations
1
Department of Family Medicine, Carilion Clinic and Virginia Tech Carilion Family Medicine Residency, Roanoke, VA.
2
Department of Endocrinology, Carilion Clinic and Virginia Tech Carilion School of Medicine, Roanoke, VA.
3
Department of Surgery, Carilion Clinic and Virginia Tech Carilion School of Medicine, Roanoke, VA.
4
Dominion Pathology Associates, Roanoke, VA.
5
Department of Basic Science Education, Virginia Tech Carilion School of Medicine, Roanoke, VA.
PMID:
35983426
PMCID:
PMC9331616
DOI:
10.2337/cd21-0118
No abstract available